Centrafarm

What Centrafarm does

Centrafarm Nederland B.V. is a Dutch pharmaceutical company founded in 1961 in Rotterdam (per company history) and now headquartered in Breda, Netherlands, operating as a wholly-owned subsidiary of STADA Arzneimittel AG, a German generics group operating in approximately 120 countries. The company is structured around a three-pillar product strategy covering (1) generic prescription medicines — a portfolio of approximately 400 active generic drugs that Centrafarm brings to market after the patents on originator products expire; (2) specialty pharmaceuticals and biosimilars developed to match biotechnologically produced reference medicines; and (3) Consumer Healthcare (OTC) products available without prescription at pharmacies, drugstores, supermarkets, and online retailers. The OTC portfolio includes established brands such as Bisolvon, Allegra, Dulcolax, Dulcosoft, Maalox, Hirudoid, Venoruton, Mobilat, and Healthypharm, alongside niche products targeting food intolerances (Fructosin, Lactosolv, Daosin) and head-lice treatment (XT luis). Distribution is fully outsourced to external wholesalers, and the company is supported by a regulatory affairs, supply chain, and product management function headquartered in Breda.

The business model is B2B2C, with revenue generated through wholesale and channel sales of registered pharmaceutical products to Dutch pharmacies, drugstore chains (DA, Etos, Kruidvat, Trekpleister), supermarkets, and online pharmacies; Centrafarm does not disclose pricing publicly. Its core technology stack is fundamentally regulatory rather than algorithmic: products are subject to quality controls by the Dutch College ter Beoordeling van Geneesmiddelen (CBG), and Centrafarm's Compliance Management System has been independently audited and certified by EY under German assurance standard 980 and ISO standards 19600 and 37301. Volume indicators point to a substantial mid-sized operator: approximately 42.3 million packages sold annually across roughly 753 total SKUs (about 400 actively marketed generics at any time), supported by a team of approximately 50-60 employees led by General Manager Jurgen Reijn. Since 2021, Centrafarm has participated in the STADA Health Report research initiative covering Dutch respondents, reflecting modest brand-building activity beyond direct product sales.

Name

Centrafarm

Legal name

Centrafarm Nederland B.V.

Website

https://centrafarm.nl

Company type

Private

Founded year

1961

Operating status

Operating

Headcount range

51–100 employees

Short description

Centrafarm Nederland B.V. is a Breda-based Dutch subsidiary of STADA Arzneimittel AG that registers, markets, and sells approximately 400 generic medicines, specialty/biosimilar pharmaceuticals, and OTC consumer healthcare brands through pharmacies, drugstores, supermarkets, and online retailers in the Netherlands.

Ownership category

akta.pro rank

Product category

Generic Pharmaceuticals

NAICS

Drugs and Druggists' Sundries Merchant Wholesalers (424210), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro industry

PRIMARYHLAIABAJ

Generic ANDA/Regulatory Affairs & Submissions

Healthcare & Life Sciences/Pharmaceuticals/Generic Pharmaceuticals

SECONDARYCRAOAHAC

Pharmacy Supply Chain & Secondary Distribution (Repackagers/Redistributors)

Consumer Products & Retail/Wholesale, Distribution & Category Management/Health, OTC & Pharmacy Wholesale Distribution

Keywords

• Generic pharmaceuticals
• OTC medicines
• Biosimilars distribution
• Consumer healthcare products
• Specialty medicines

Headquarters

HQ city

Breda

HQ country

Netherlands

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Supply Chain, Operations, Marketing or Sales, Technology or R&D, Infrastructure

Revenue model

1. Generic Medicines Sales: Sales of generic pharmaceutical products including prescription drugs (Rx), Over-The-Counter (OTC) medicines, and branded Consumer Healthcare products through pharmacies, drugstores, and supermarkets.

Go-to-market motion1 record

Distribution channels4 records

Marketing channels3 records

Core offering

Centrafarm is the Dutch pharmaceutical sales and marketing subsidiary of STADA Arzneimittel AG. It registers, markets, and sells a portfolio of approximately 400 generic prescription medicines, specialty drugs and biosimilars, and OTC/Consumer Healthcare products (including brands such as Allegra, Bisolvon, Dulcolax/Dulcosoft, Healthypharm, Maalox, Hirudoid, Venoruton, and Mobilat) through Dutch pharmacies, drugstores, and supermarkets.

Product overview

Centrafarm is a Dutch pharmaceutical company offering a three-pillar product strategy consisting of generic medicines, specialties & biosimilars, and consumer healthcare. The company operates as a subsidiary of STADA Arzneimittel AG and markets approximately 400 generic medicines alongside an OTC portfolio including brands such as Allegra (fexotabs and nasal spray), Dulcolax/Dulcosoft (laxatives), Bisolvon, Healthypharm, Maalox, Hirudoid, Venoruton, Mobilat, and products for food intolerance (Fructosin, Lactosolv, Daosin). The prescription medicines portfolio includes specialty products across therapeutic areas such as anticoagulants (rivaroxaban, dabigatran), dermatology (acitretine, teriflunomide), neurology/psychiatry (quetiapine, lisdexamfetamine, valproaat), infectious diseases (emtricitabine/tenofovir, voriconazol), and gastroenterology (lecigon). Products are available through pharmacies, drugstores, and supermarkets across the Netherlands.

Differentiator

Problem solved

Functional benefit

Brands

• Bisolvon: Cough remedy product for treating cough symptoms.
• Allegra
• Healthypharm
• XT luis
• Fructosin
• Lactosolv
• Daosin
• Dulcolax
• Dulcosoft
• Maalox
• Hirudoid
• Venoruton
• Mobilat

Products and services

• Generieke geneesmiddelen (Generic Medicines) Generic prescription and OTC-equivalent medicines marketed in the Netherlands after the patent of the original branded medication expires; portfolio of approximately 400 products supplied to Dutch pharmacies.
• Specialties & Biosimilars Specialty medicines and biosimilars developed to closely match biotechnologically produced reference medicines (biopharmaceuticals), marketed in the Netherlands via the STADA biosimilars platform.
• Consumer Healthcare (OTC) Products

Quantifiable outcome

• 42.3 million packages sold per year
• +1 more outcomes

Segments1 record

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Scale indicators6 records

Recent moves7 records

Expansion highlights5 records

Emerging players

• Glenmark Pharmaceuticals: India-based generic and specialty pharma with growing European presence, including the Netherlands, marketing generics and OTC products through pharmacy and drugstore channels comparable to Centrafarm's GTM.
• Cipla: India-based global pharmaceutical company expanding its European generics and biosimilars portfolio, with comparable go-to-market in pharmacy channels and overlap in therapeutic categories such as respiratory and allergy.

Direct peers

• Viatris: Formed from Mylan-Upjohn combination, Viatris is a major global generics player with an established European commercial network marketing generic and branded generics, including OTC, across pharmacy channels comparable to Centrafarm's portfolio.
• Teva Pharmaceutical Industries: World's largest generic drug manufacturer with a strong European footprint, selling generic and specialty medicines through pharmacy and drugstore channels—directly comparable in product mix, customer base, and channel strategy.
• Sandoz: Global generics and biosimilars leader spun out of Novartis; directly comparable to Centrafarm as it markets generic and biosimilar medicines across European markets including the Netherlands through pharmacy and hospital channels.
• Sun Pharmaceutical Industries: Largest Indian specialty generics manufacturer with commercial presence in Europe; comparable in product mix (generics, specialty) and route-to-market through Dutch pharmacy distribution.
• Aurobindo Pharma: India-based global generic manufacturer with significant European operations distributing through pharmacy chains, directly comparable to Centrafarm in generic Rx and OTC supply to the Dutch market.
• Apotex: Canadian-headquartered generic pharmaceutical company with European operations selling into pharmacy channels, comparable to Centrafarm in generic medicines and OTC product offerings.

Broad incumbents

• STADA Arzneimittel AG: Parent company of Centrafarm; the broader STADA Group is a pan-European generics, specialty, and Consumer Healthcare company, comparable as a parent context for Centrafarm's strategy and product portfolio.

Regional players

• Aspen Pharmacare: South African-headquartered specialty and generics company with European commercial operations; comparable as a non-European-headquartered generic and OTC player selling into European pharmacy channels.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/centrafarm-nederland-bv

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Centrafarm